Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
ConditionRecurrent Glioblastoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Miami
About this trial
The purpose of this research is to find hidden cancer with an experimental magnetic resonance imaging (MRI) scan called spectroscopic magnetic resonance imaging (sMRI). That spectroscopic MRI scan will be used to increase the area of the brain receiving radiation and then the dose of radiation in attempt to kill more of the cancer. Proton radiotherapy and bevacizumab (Avastin) are used to minimize the possible side effects of this approach.
Eligibility criteria
Qualifiers
An area of MRI enhancement consistent with glioblastoma outside of the initial high dose radiation field.
Biopsy or resection proven recurrent glioblastoma.
Progressive glioblastoma based on advanced imaging (brain positron emission tomography (PET), perfusion MRI, or clinical MR Spectroscopy)
For "marginal" or "out of field" radiation failures where at least half of the enhancing disease is outside of the prior high dose radiation field but there is field overlap, patients must have completed prior radiation at least four months or more prior to study treatment.
Disqualifiers
Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months prior to registration.
Transmural myocardial infarction within the last 6 months prior to registration.
History of stroke or transient ischemic attack within 6 months prior to registration.
Significant vascular disease (e.g., aortic aneurysm, history of aortic dissection) or clinically significant peripheral vascular disease.
Trial design
Treatments tested in this trial
- Intensity Modulated Proton Therapy (IMPT)
- Bevacizumab
Treatment groups
96 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov